2-OH-E1 % is the percentage of estrone (E1) that your body converts down the 2-hydroxylation pathway to 2-hydroxyestrone. It’s a distribution marker, not a raw hormone level: it shows how your estrogen metabolism is partitioned among pathways (2-OH, 4-OH, 16-OH). Results are reported from a spot urine sample, typically normalized to creatinine, so hydration has less impact.
Why it matters
Your body breaks down estrogens through several Phase I pathways:
-
2-hydroxylation (this marker): makes 2-hydroxyestrone, a less estrogenic “catechol” estrogen. It is usually considered a benign/neutral route when it is subsequently methylated by COMT to 2-methoxy metabolites.
-
4-hydroxylation: produces reactive catechols that can form quinones if not well methylated/neutralized.
-
16-hydroxylation: yields 16α-OH-E1, a more estrogenic metabolite that can act longer at receptors.
A healthy pattern is balanced, within your lab’s reference ranges. This marker does not diagnose cancer risk and shouldn’t be used alone to predict disease—it’s a metabolic snapshot that helps you and your clinician see where estrogen is being routed.
How to read your result (always use your lab’s reference range)
-
Lower 2-OH-E1 % (shift away from 2-pathway):
Suggests a relative preference for 16-OH and/or 4-OH pathways. In context with other metabolites, this may reflect lower CYP1A activity, certain medications, or lifestyle factors. Clinically, the goal is not “max 2-OH,” but an appropriate balance with good downstream neutralization (methylation, glucuronidation, sulfation). -
Higher 2-OH-E1 % (shift toward 2-pathway):
Indicates more estrone is routed to 2-hydroxylation. On its own, that’s often fine—especially if 2-methoxy metabolites are also adequate (showing COMT is methylating well). If 2-OH-E1 % is high but 2-methoxy levels are low, discuss methylation support and overall antioxidant status with your clinician.
Pair this marker with its “downstream” partner. High 2-OH alongside low 2-methoxy suggests bottlenecks in methylation (COMT); low 2-OH with high 16-OH shows a different pattern and a different plan.
What can influence 2-OH-E1 %
-
Dietary patterns: Cruciferous vegetables (broccoli, kale, cabbage), I3C/DIM supplements, and a diet rich in polyphenols can tilt metabolism toward 2-hydroxylation; always use supplements judiciously and with clinician guidance.
-
Alcohol, caffeine, tobacco smoke, and charred foods: Can modify CYP enzymes (Phase I) and shift pathway percentages.
-
Medications/supplements: Certain drugs (e.g., enzyme inducers/inhibitors), proton-pump inhibitors, St. John’s wort, and others may change Phase I/II balance. Hormonal contraception and HRT alter overall estrogen production and metabolite patterns.
-
Methylation capacity (COMT) & Phase II pathways: Adequate folate, B12, B6, magnesium, and choline/betaine support methylation; fiber and hydration aid glucuronidation/excretion.
-
Cycle timing & collection: Aim for consistent timing (many labs prefer early follicular) and a first-morning urine sample for comparisons.
What to do next (actionable plan)
If your 2-OH-E1 % is low (relative shift to 16-/4-OH):
-
Recheck under optimal collection conditions; 2) Review medications and alcohol/smoking; 3) Discuss with your clinician adding/lifestyle sources of crucifers and overall plant diversity; 4) Ensure adequate fiber (25–35 g/day), sleep, and exercise, which support Phase II clearance; 5) Consider whether I3C/DIM is appropriate (clinician-guided), especially if 16-OH is relatively high.
If your 2-OH-E1 % is high:
-
Confirm that 2-methoxy metabolites are also sufficient—good methylation helps neutralize catechols; 2) If methoxy is low, prioritize methylation nutrients (food-first; supplements only with guidance), manage alcohol, and consider stress/sleep optimization; 3) Keep perspective—a high percentage alone isn’t harmful, but balance across pathways matters.
If any result is far outside range or symptoms are significant (cycle irregularity, heavy bleeding, hot flashes/night sweats out of the expected life stage, new breast symptoms): follow up with your clinician for targeted serum testing (estradiol, estrone, SHBG), pelvic evaluation when appropriate, and a review of thyroid, iron, and metabolic markers.
FAQs
Does a higher 2-OH-E1 % mean lower breast-cancer risk?
Not necessarily. Research on ratios/percentages and risk is mixed. Use this marker to understand metabolism, not to predict risk or guide treatment by itself.
Can I fix a “low” 2-OH-E1 % with supplements?
Sometimes dietary changes (crucifers, fiber, whole-foods pattern) help. Supplements like DIM/I3C can alter metabolism but aren’t for everyone—work with your clinician and re-test rather than self-treating.
Is more 2-OH always better?
No. The key is balance and downstream methylation (adequate 2-methoxy). An extreme shift without good Phase II support isn’t the goal.
Key takeaways
-
2-OH-E1 % shows the share of estrone routed to 2-hydroxylation; it’s a distribution metric, not a disease diagnosis.
-
Low %: relative shift toward 16-/4-OH; consider diet, lifestyle, and medication factors.
-
High %: more 2-OH routing—fine if 2-methoxy is adequate; if not, consider methylation support.
-
Aim for balanced pathways within your lab’s ranges, guided by your symptoms and clinician input.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.